Literature DB >> 6447666

Frequencies of alloreactive cytotoxic T-lymphocyte precursors responding to H-2 antigens alone.

R Ceredig.   

Abstract

The experiments reported here were designed to investigate the role of major histocompatibility antigens alone in primary allogeneic responses in vitro. Mixed lymphocyte cultures were established using small numbers of responder spleen cells and semiallogeneic or fully allogeneic stimulator spleen cells. The cytotoxicity generated in individual cultures was then detected by a sensitive 51Cr-release assay and the frequencies of responding cytotoxic T lymphocyte precursors (CTL-P) determined by limit dilution analysis. To investigate the responses of spleen cells to major histocompatibility (H-2) antigens alone, strains of BALB/c mice congenic at the H-2 locus were used as responder and stimulator cells. The frequencies of CTL-P responding in such congenic combinations were compared with those obtained using mouse strain combinations differing at minor histocompatibility (minor-H) loci in addition to H-2. A similar fraction of spleen cells responded regardless of whether the stimulator cells differed at the H-2 locus alone or at multiple minor-H loci in addition to H-2. It was concluded that minor-H antigenic differences do not contribute significantly to allogeneic responses.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6447666      PMCID: PMC1458000     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  20 in total

1.  A comparison of immune responses against AG-B and non-AG-B antigens, presented alone or together.

Authors:  P M Chisholm; M E Smith; S M Sparshott; W L Ford
Journal:  Transplantation       Date:  1977-06       Impact factor: 4.939

2.  Standardized nomenclature for inbred strains of mice: sixth listing.

Authors:  J Staats
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

3.  Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens?

Authors:  P Matzinger; M J Bevan
Journal:  Cell Immunol       Date:  1977-03-01       Impact factor: 4.868

4.  Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Nature       Date:  1974-10-11       Impact factor: 49.962

5.  Allograft immunity in the mouse. 1. Quantitation and specificity of cytotoxic effector cells after in vitro sensitization.

Authors:  H R MacDonald; R A Phillips; R G Miller
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

Review 6.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

7.  Specificity of virus-immune effector T cells for H-2K or H-2D compatible interactions: implications for H-antigen diversity.

Authors:  P C Doherty; R V Blanden; R M Zinkernagel
Journal:  Transplant Rev       Date:  1976

8.  Early cellular events in a systemic graft-vs.-host reaction. II. Autoradiographic estimates of the frequency of donor lymphocytes which respond to each Ag-B-determined antigenic complex.

Authors:  W L Ford; S J Simmonds; R C Atkins
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

9.  In vitro cell-mediated immune responses to the male specific(H-Y) antigen in mice.

Authors:  R D Gordon; E Simpson; L E Samelson
Journal:  J Exp Med       Date:  1975-11-01       Impact factor: 14.307

10.  An estimation of the frequency of precursor cells which generate cytotoxic lymphocytes.

Authors:  M A Skinner; J Marbrook
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

View more
  1 in total

1.  T-cell hyperreactivity of NZB mice against H-2 identical cells. Equal cytotoxic T lymphocyte precursor frequency against H-2 allogeneic and H-2 syngeneic target cells in NZB.

Authors:  J Müller; R Bartlett; U Botzenhardt
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.